梁欣 博士
副教授，碩士生導(dǎo)師
郵箱：xin.liang@ecust.edu.cn
地址：上海市徐匯區(qū)梅隴路130號(hào)實(shí)驗(yàn)十八樓633室；
郵編：200237
個(gè)人簡(jiǎn)歷：
2003.9-2007.6 華東理工大學(xué)生物工程專業(yè)，工學(xué)學(xué)士
2007.9-2012.3 華東理工大學(xué)生物化工專業(yè)，工學(xué)博士
2012.7-2015.5 美國(guó)埃默里大學(xué)（Emory University）Renhao Li’s Lab 博士后
2015.7-2016.8 華東理工大學(xué)藥學(xué)院，講師
2016.9至今 華東理工大學(xué)藥學(xué)院，副教授
作為項(xiàng)目負(fù)責(zé)人主持國(guó)家自然科學(xué)基金，上海市自然科學(xué)基金，教育部基本科研業(yè)務(wù)費(fèi)探索研究基金等。
研究方向：
主要研究領(lǐng)域?yàn)?/span>腫瘤轉(zhuǎn)移以及微環(huán)境的相互作用研究。包括血小板參與腫瘤轉(zhuǎn)移微環(huán)境形成的機(jī)制研究，miRNA在腫瘤轉(zhuǎn)移以及微環(huán)境中的相互作用研究，小分子化合物或抗體藥物的抗腫瘤機(jī)制研究。
招生專業(yè)：
學(xué)術(shù)型碩士-藥學(xué)（代碼：100700）；專業(yè)型碩士-藥學(xué)（代碼：105500）
代表性論文：
1. Zhu Y, Zhu Y, Deng Q, Liang X*. Hepatitis B Virus X Protein es VWF-mediated HCC progression through ST8SIA6-AS1/miR-3150b-3p/ASCL1 axis. Eur J Pharmacol. 2025 Mar 15;991:177315.
2. Zhu Y, Gu J, Lu Y, Tao Q, Cao X, Zhu Y, Yang M*, Liang X*. IL-6 Released from Hepatic Stellate Cells Promotes Glycolysis and Migration of HCC Through the JAK1/vWF/TGFB1 Axis. J Hepatocell Carcinoma. 2024 Jul 5;11:1295-1310.
3. Lu Y, Qi Y, Gu J, Tao Q, Zhu Y, Zhang H, Liang X*. Vascular endothelial-derived Von Willebrand factor inhibits lung cancer progression through the αvβ3/ERK1/2 axis. Toxicol Appl Pharmacol. 2023;468:116516.
4. Tao Q, Qi Y, Gu J, Yu D, Lu Y, Liu J, Liang X*. Breast cancer cells-derived Von Willebrand Factor es VEGF-A-related angiogenesis through PI3K/Akt-miR-205-5p signaling pathway. Toxicol Appl Pharmacol. 2022; 440: 115927.
5. Tao Q, Lu Y, Qi Y, Yu D, Gu J, Zhu Y, Shi C*, Liang X*. Hypoxia es the expression of Von Willebrand factor in breast cancer cells by up-regulating the transcription factor YY1 and down-regulating the hsa-miR-424. Eur J Pharmacol. 2022; 934: 175308.
6. Gu J, Qi Y, Lu Y, Tao Q, Yu D, Jiang C, Liu J, Liang X*. Lung adenocarcinoma-derived vWF es tumor metastasis by regulating PHKG1-mediated glycogen metabolism. Cancer Sci. 2022; 113(4): 1362- 1376.
7. Yin Q, Gu J, Qi Y, Lu Y, Yang L, Liu J*, Liang X*. ADAM28 from both endothelium and gastric cancer cleaves von Willebrand Factor to eliminate von Willebrand Factor-induced apoptosis of gastric cancer cells. Eur J Pharmacol. 2021, 898:173994.
8. Zhao Y, Tao Q, Li S, Zheng P*, Liu J, Liang X*. Both endogenous and exogenous miR-139-5p inhibit Fusobacterium nucleatum-related colorectal cancer development. Eur J Pharmacol. 2020, 888:173459.
9. Zhao Y, Xu J, Le V, Gong Q, Li S, Gao F, Ni L*, Liu J*, Liang X*. Epcam aptamer-functionalized cationic liposome-based nanoparticles loaded with mir-139-5p for targeted therapy in colorectal cancer. Molecular Pharmaceutics. 2019, 16(11): 4696-4710.
10. Qi Y, Chen W, Liang X, Xu K*, Gu X, Wu F, Fan X, Ren S, Liu J, Zhang J, Li R, Liu J*, Liang X*. Novel antibodies against GPIbα inhibit pulmonary metastasis by affecting vWF-GPIbα interaction. Journal of Hematology & Oncology. 2018, 11(1):117.
